F
Frangiscos Sifakis
Researcher at AstraZeneca
Publications - 26
Citations - 1275
Frangiscos Sifakis is an academic researcher from AstraZeneca. The author has contributed to research in topics: Population & Cohort study. The author has an hindex of 13, co-authored 26 publications receiving 932 citations. Previous affiliations of Frangiscos Sifakis include Boehringer Ingelheim & MedImmune.
Papers
More filters
Journal ArticleDOI
A systematic review of risk factors associated with surgical site infections among surgical patients.
Ellen E. Korol,Karissa Johnston,Nathalie Waser,Frangiscos Sifakis,Hasan S. Jafri,Mathew Lo,Moe H. Kyaw +6 more
TL;DR: Risk factors consistently identified as associated with SSI included co-morbidities, advanced age, risk indices, patient frailty, and surgery complexity, which allows for identification of patients with the greatest need for optimal preventive measures to be identified and pre-treatment prior to surgery.
Journal ArticleDOI
Surveillance for control of antimicrobial resistance
Evelina Tacconelli,Frangiscos Sifakis,Stéphan Juergen Harbarth,Remco Schrijver,Maaike S. M. van Mourik,Andreas Voss,Mike Sharland,Nithya Babu Rajendran,Jesús Rodríguez-Baño,Julia Bielicki,Marlieke E. A. de Kraker,Sumanth Gandra,Petra Gastmeier,Kim Gilchrist,Achilleas Gikas,Beryl Primrose Gladstone,Herman Goossens,Hasan S. Jafri,Gunnar Kahlmeter,F.R. Leus,Christine Luxemburger,Surbhi Malhotra-Kumar,Giuseppe Marasca,Michael P. McCarthy,María Dolores González-Ripoll Navarro,María Núñez-Núñez,Abdel Oualim,Jessica Price,Jérôme Robert,Harriet Sommer,Maja von Cube,Cuong Vuong,Irith Wiegand,Anne Therese Witschi,Martin Wolkewitz +34 more
TL;DR: In Europe, improvement of national antimicrobial resistance surveillance systems and better alignment between human and veterinary surveillance systems in Europe must become a scientific and political priority, coordinated with international stakeholders within a global approach to reduce the burden of antimicrobial resistant bacteria.
Journal ArticleDOI
Age-Specific Prevalence of Epstein–Barr Virus Infection Among Individuals Aged 6–19 Years in the United States and Factors Affecting Its Acquisition
Henry H. Balfour,Frangiscos Sifakis,Joseph A. Sliman,Jennifer A. Knight,David O. Schmeling,William Thomas +5 more
TL;DR: The declining antibody prevalence over time and the consistently high observed prevalence among participants aged 12-19 years support broad use of EBV vaccine before 12 years of age.
Journal ArticleDOI
Medically Attended Respiratory Syncytial Virus Infections in Adults Aged ≥50 Years: Clinical Characteristics and Outcomes
TL;DR: Patients with RSV were older and sought care later in the course of illness compared to those with influenza, and they were also more likely to be diagnosed with pneumonia.
Journal ArticleDOI
Respiratory Syncytial Virus Disease in Preterm Infants in the US Born at 32–35 Weeks Gestation Not Receiving Immunoprophylaxis
Christopher S. Ambrose,Evan J. Anderson,Eric A. F. Simões,Xionghua Wu,Hanaa Elhefni,C. Lucy Park,Frangiscos Sifakis,Jessie R. Groothuis +7 more
TL;DR: In US preterm infants who were 32–35 weeks gestational age on November 1st and not receiving RSV prophylaxis, the burden of RSV MAARI was 25 per 100 infant-seasons, and the highest RSVH rates occurred among those with daycare attendance or nonmultiple-birth, preschool-aged siblings while they were <6 months of age during the RSV season.